Zostavax in Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

October 31, 2012

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

Zostavax vaccine

Commercially available Zostavax vaccine will be administered subcutaneously according to package insert guidelines. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV.

Trial Locations (1)

73104

Oklahoma Medical Research Foundation, Oklahoma City

All Listed Sponsors
lead

Oklahoma Medical Research Foundation

OTHER

NCT01474720 - Zostavax in Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter